Previous 10 | Next 10 |
- Initiation of LYNX Phase 2 clinical trial in individuals with DMD expected in Q4 2022 - Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for the treatment of rare muscle ...
Edgewise Therapeutics press release ( NASDAQ: EWTX ): Q2 GAAP EPS of -$0.32 beats by $0.02 . Cash, cash equivalents and marketable securities of $248.4 million as of June 30, 2022 For further details see: Edgewise Therapeutics GAAP EPS of -$0.32 beats by $0.0...
– Announced positive 2-month interim results from the ARCH open label study of EDG-5506 in adults with Becker muscular dystrophy (BMD) – – Initiated Phase 2 trial in BMD; Expect to start Phase 2 trial in Duchenne muscular dystrophy (DMD) in 2022 –...
Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for the treatment of rare muscle disorders, announced today that members of its senior management team will participate in a panel ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips This article covers six blue-chip stocks to sell now. These stocks are severely overvalued or are likely to move down soon due to the coming recession or a slump in demand. The point is analysts’ forecasts are like...
Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for the treatment of rare muscle disorders, today announced the initiation of the CANYON Phase 2 clinical trial evaluating EDG-5506...
– EDG-5506 treatment significantly lowered muscle damage biomarkers in adults with BMD – – BMD patients were more active during 2 months of dosing with EDG-5506 relative to activity measured in BMD patients in the Phase 1 study – ...
- Edgewise management to host webcast conference call on Tuesday, June 21, 2022 at 9 a.m. Eastern Time - - Additional presentations and posters featuring EDG-5506 to be featured at the New Directions Conference and the upcoming PPMD Annual Conference - Ed...
Halvorsen's 13F portfolio value decreased from $34.49B to $24.74B this quarter. The number of positions decreased from 107 to 56. Viking Global increased Amazon.com, Fortive, and International Flavors & Fragrances while dropping Humana, Coupa Software, and Twilio. The top thre...
The following slide deck was published by Edgewise Therapeutics, Inc. in conjunction with this event. For further details see: Edgewise Therapeutics (EWTX) Investor Presentation - Slideshow
News, Short Squeeze, Breakout and More Instantly...
Edgewise Therapeutics Inc. Company Name:
EWTX Stock Symbol:
NASDAQ Market:
Edgewise Therapeutics Inc. Website:
2024-07-01 09:22:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-21 10:32:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-05-30 19:16:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...